Clinical pharmacists' interventions for preventing adverse events in critically ill neonates in Qatar: an economic...

Area of Science:

• Pharmacoeconomics
• Neonatal Intensive Care Unit (NICU) Pharmacy Practice

Background:

• Clinical pharmacists play a crucial role in optimizing medication therapy in neonatal intensive care units (NICUs).
• Assessing the economic impact of these interventions is vital for resource allocation and demonstrating value.

Purpose of the Study:

• To evaluate the overall economic impact of clinical pharmacist interventions within a neonatal intensive care unit (NICU) in Qatar.
• To quantify cost avoidance from preventable adverse drug events (ADEs) and cost savings from revised resource utilization.

Main Methods:

• Retrospective review of 150 neonates' records over a 3-month period in a Qatari NICU.
• Calculation of total economic benefit by summing cost avoidance (preventable ADEs) and cost savings (resource use adjustments).
• Sensitivity analyses were performed to validate findings.

Main Results:

• 513 interventions were analyzed, primarily addressing therapy dosing, drug choice, prophylactic treatment, and administration frequency.
• The estimated annual economic benefit was QAR 4,178,352 (USD 1,147,584).
• This included QAR 1,050,680 (USD 288,648) in cost avoidance and QAR -6091 (USD -1673) in cost savings.

Conclusions:

• Despite increased resource utilization, clinical pharmacist interventions in the NICU setting demonstrate significant economic benefits.
• The primary economic advantage stems from avoiding costs associated with adverse drug events.
• These findings underscore the cost-effectiveness of specialized pharmacy services in neonatal care.